Published in Biol Blood Marrow Transplant on March 01, 2009
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants | NCT00106925
How I treat late effects in adults after allogeneic stem cell transplantation. Blood (2010) 1.26
Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Exp Hematol (2013) 0.98
NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks. Biol Blood Marrow Transplant (2011) 0.96
Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2010) 0.95
Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients. Bone Marrow Transplant (2015) 0.78
Endocrinopathies in survivors of childhood neoplasia. Front Pediatr (2014) 0.76
Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease? Croat Med J (2016) 0.75
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol (1991) 3.21
Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplant (2005) 2.13
Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol (2005) 2.11
Solid cancers after bone marrow transplantation. J Clin Oncol (2001) 1.99
Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med (1999) 1.59
Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol (2008) 1.37
Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.21
Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab (2004) 1.19
Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant (2005) 1.17
Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood (2008) 1.17
TSH-activated signaling pathways in thyroid tumorigenesis. Mol Cell Endocrinol (2003) 1.11
Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation. Bone Marrow Transplant (1995) 1.10
High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer (2002) 1.08
Thyroid function in children after allogeneic bone marrow transplantation. Bone Marrow Transplant (1994) 1.04
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant (2006) 1.04
Endocrine function following single fraction and fractionated total body irradiation for bone marrow transplantation in childhood. Acta Endocrinol (Copenh) (1993) 0.98
Short- and long-term follow-up of thyroid dysfunction after allogeneic bone marrow transplantation without the use of preparative total body irradiation. Br J Haematol (1997) 0.92
Subclinical thyroid disease. Am Fam Physician (2005) 0.89
Thyroid function after bone marrow transplantation: possible association between immune-mediated thyrotoxicosis and hypothyroidism. Transplantation (2001) 0.89
Effects of thyroid-stimulating hormone on human thyroid carcinoma and adjacent normal tissue. J Clin Endocrinol Metab (1978) 0.82
Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta (1986) 13.69
A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res (1982) 7.12
Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol (1981) 6.84
The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99
Evolutionary families of peptidases. Biochem J (1993) 5.81
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J (1982) 5.67
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Human cathepsin B1. Purification and some properties of the enzyme. Biochem J (1973) 4.06
The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. Biochem J (1979) 3.58
Evolutionary families of metallopeptidases. Methods Enzymol (1995) 3.48
A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem (1979) 3.17
Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J (1970) 3.09
Families of serine peptidases. Methods Enzymol (1994) 2.94
A new assay for cathepsin B1 and other thiol proteinases. Anal Biochem (1972) 2.93
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J (1974) 2.65
Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. Biochem J (1971) 2.60
MEROPS: the peptidase database. Nucleic Acids Res (1999) 2.60
Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet (1979) 2.48
An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature (1998) 2.44
Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J (1983) 2.42
Pectic polysaccharides of growing plant tissues. Biochem J (1967) 2.24
Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2.22
Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J (1980) 2.20
Neutral proteinases of human spleen. Purification and criteria for homogeneity of elastase and cathepsin G. Biochem J (1976) 2.17
Human liver cathepsin L. Biochem J (1985) 2.16
Lysosomal acid proteinase of rabbit liver. Biochem J (1967) 2.12
The interaction of alpha2-macroglobulin with proteinases. Binding and inhibition of mammalian collagenases and other metal proteinases. Biochem J (1974) 2.11
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood (2001) 2.11
The inhibition of tissue acid proteinases by pepstatin. Biochem J (1972) 2.06
Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem (1986) 2.03
CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys (1992) 2.03
Hepatitis-associated aplastic anemia. N Engl J Med (1997) 1.98
Families of cysteine peptidases. Methods Enzymol (1994) 1.98
Hypertension and convulsions in children receiving cyclosporin A. Lancet (1982) 1.89
Human cathepsin H. Biochem J (1980) 1.88
An improved color reagent for use in Barrett's assay of Cathepsin B. Anal Biochem (1976) 1.87
Action of rat liver cathepsin L on collagen and other substrates. Biochem J (1982) 1.73
Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem J (1986) 1.71
Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin. Biochem J (1984) 1.69
MEROPS: the peptidase database. Nucleic Acids Res (2000) 1.69
Human cathepsin G. Catalytic and immunological properties. Biochem J (1976) 1.65
Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunother (2006) 1.65
The many forms and functions of cellular proteinases. Fed Proc (1980) 1.64
Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet (1983) 1.64
Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem (1997) 1.63
Chicken alpha2-proteinase inhibitor: a serum protein homologous with ovoinhibitor of egg white. Biochim Biophys Acta (1974) 1.63
Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen 1. Biol Chem Hoppe Seyler (1988) 1.63
The degradation of cartilage proteoglycans by tissue proteinases. Proteoglycan structure and its susceptibility to proteolysis. Biochem J (1977) 1.63
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood (1997) 1.63
Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem (1987) 1.61
Human lysosomal elastase. Catalytic and immunological properties. Biochem J (1976) 1.59
The degradation of articular collagen by neutrophil proteinases. Biochim Biophys Acta (1977) 1.59
Lysosomes. Essays Biochem (1976) 1.58
Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood (2006) 1.57
The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun (1984) 1.56
Alpha 2-macroglobulin. Methods Enzymol (1981) 1.55
Human plasma kallikrein. A rapid purification method with high yield. Biochem J (1981) 1.53
Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem (1999) 1.52
Degradation of fructose-1,6-bisphosphate aldolase by cathepsin B. Biochem J (1980) 1.52
Lysis and killing of bacteria by lysosomal proteinases. Infect Immun (1976) 1.50
Calpain inhibition by peptide epoxides. Biochem J (1985) 1.49
Elastinolytic activity of human cathepsin L. Biochem J (1986) 1.48
The possible role of neutrophil proteinases in damage to articular cartilage. Agents Actions (1978) 1.48
Specific inhibition of cartilage breakdown. Nature (1969) 1.47
The effects of proteolytic enzymes on the mechanical properties of adult human articular cartilage. Biochim Biophys Acta (1976) 1.47
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood (1999) 1.47
Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol (2001) 1.46
Purification of cathepsin B by a new form of affinity chromatography. Biochem J (1986) 1.45
Chymopapain. Chromatographic purification and immunological characterization. Biochem J (1984) 1.45
Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant (2007) 1.44
Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood (2001) 1.44
The specificity of cathepsin B. Hydrolysis of glucagon at the C-terminus by a peptidyldipeptidase mechanism. Biochem J (1978) 1.44
Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor. Br J Haematol (1991) 1.42
Covalent binding of proteinases in their reaction with alpha 2-macroglobulin. Biochem J (1980) 1.41
Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia. Exp Hematol (1995) 1.40
A new family of serine-type peptidases related to prolyl oligopeptidase. Biochem J (1991) 1.40
Inhibition by alpha-macroglobulin and other serum proteins. Biochem J (1973) 1.40
Interaction of human cathepsin D with the inhibitor pepstatin. Biochem J (1976) 1.39
The degradation of human glomerular basement membrane with purified lysosomal proteinases: evidence for the pathogenic role of the polymorphonuclear leucocyte in glomerulonephritis. Clin Sci Mol Med (1978) 1.38
Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant (2004) 1.37
Further characterization of the covalent linking reaction of alpha 2-macroglobulin. Biochem J (1981) 1.35
Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. Br Med J (Clin Res Ed) (1982) 1.35
Evolution of proteins of the cystatin superfamily. J Mol Evol (1990) 1.34
Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. FEBS Lett (1998) 1.33
Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem J (1986) 1.32
Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum (1993) 1.30
Cystatin-like cysteine proteinase inhibitors from human liver. Biochem J (1984) 1.30
Proteoglycan-degrading enzymes. A radiochemical assay method and the detection of a new enzyme cathepsin F. Biochem J (1977) 1.30
Immunoinhibition of intracellular protein digestion in macrophages. J Exp Med (1973) 1.29
Cathepsins BI and D. Action on human cartilage proteoglycans. Biochim Biophys Acta (1973) 1.29
Cathepsin G. Methods Enzymol (1981) 1.29
An alternative quenched fluorescence substrate for Pz-peptidase. Anal Biochem (1990) 1.27
Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis (2001) 1.26
Affinity purification and biochemical characterization of histolysin, the major cysteine proteinase of Entamoeba histolytica. Biochem J (1988) 1.26
Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant (1998) 1.25